Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Denosumab Market In 2029?
The market for denosumab has expanded swiftly in the last few years. It is projected to grow from $3.27 billion in 2024 to $3.67 billion in 2025, with a compound annual growth rate (CAGR) of 12.1%. The expansion in the preceding years can be credited to advancements in clinical trials and research, meeting regulatory milestones and FDA approvals, an increase in bone health consciousness, as well as strategic collaboration and marketing endeavors.
Expectations for the denosumab market size indicate a swift expansion in the upcoming years. The market is projected to reach $5.48 billion in 2029 with a compound annual growth rate (CAGR) of 10.6%. The anticipated advancement in the forecast period is due to factors such as an increase in bone metastases occurrences, enhancements in cancer treatments, widespread osteoporosis, heightened osteoporosis awareness, and regulatory green lights for new indications. Key trends for the forecast period encompass strategic alliances and partnerships, combination with digital health solutions, broadened indications and clinical applications, and upgrades in biosimilar development.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Denosumab Market?
The denosumab market is anticipated to grow due to the escalating occurrence of osteoporosis. Osteoporosis is a health issue that weakens the bones, leading to decreased bone density and an elevated risk of fractures. Denosumab plays a role in treating osteoporosis by preventing bone resorption by zeroing in on the RANK ligand. As an example, data from the Canadian Longitudinal Study on Aging, released by the US-based National Center for Biotechnology Information in September 2023, revealed that physician-diagnosed osteoporosis prevalence was 12.7%, and DXA-confirmed osteoporosis stood at 5.9% in females among elder adults living in the community. Moreover, a cross-sectional study performed by Buttros and their team stated that osteoporosis was identified in 24.6% of postmenopausal women aged 40 to 75 using bone mineral density (BMD) measurements. Thus, the rising occurrence of osteoporosis is fueling denosumab market expansion.
Which Primary Segments of the Denosumab Market Are Driving Growth and Industry Transformations?
The denosumab market covered in this report is segmented –
1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Denosumab Market?# Market?
North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Denosumab Market?
Leading businesses in the denosumab market are intensifying their efforts towards the innovation of new solutions, like creating standard or prime treatment methods for osteoporosis, as a strategy to outrival other players in the market. Standard therapy for osteoporosis alludes to the frontline treatment course prescribed by medical experts for those suffering from osteoporosis. For instance, Boan Biotech, a biotech business based in China, in November 2022, was granted permission from the National Medical Products Administration (NMPA) of China to produce its denosumab biosimilar known as Boyoubei, hence becoming the pioneering Chinese company to formulate a denosumab injection. This drug is also being fashioned for markets outside China, such as Europe and the United States, and there are plans to market it globally. The drug is endorsed in various therapeutic guidelines as a standard therapy for osteoporosis. This medication could significantly reduce the likelihood of hip, non-vertebral, and vertebral fracture among patients. In addition, Boyoubei has the distinction of being the first biosimilar to Prolia (the original creator of denosumab) to receive worldwide marketing approval.
View the full report here:
https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report
What Parameters Are Used to Define the Denosumab Market?
Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting osteoclast formation, decreasing bone resorption, increasing bone mineral density, and reducing the risk of fracture.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13835
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model